On July 22, Arcus Biosciences, Inc. (NYSE:RCUS) and Summit Therapeutics Inc. (NASDAQ:SMMT) announced a major clinical trial collaboration to combine Arcus’s casdatifan (an investigational HIF-2α inhibitor) with Summit’s ivonescimab (an investigational PD-1/VEGF bispecific antibody). The study aims to evaluate the safety and efficacy of this combination in clear cell renal cell carcinoma (ccRCC), including first-line metastatic disease. Arcus CEO Terry Rosen highlighted the opportunity to establish a well-tolerated, TKI-sparing regimen that could prolong survival and serve as a first-line backbone therapy. Under the agreement, Summit Therapeutics will supply ivonescimab while Arcus sponsors and conducts the study as a new cohort in its ARC-20 platform, with both sharing costs and retaining commercial rights. Initial data is expected by mid-2027. To strengthen its broader casdatifan strategy, Arcus also inked a clinical supply pact with AVEO Oncology on July 22.
Financial Comparison: Arcus Biosciences, Inc. (NYSE:RCUS) vs. Summit Therapeutics Inc. (NASDAQ:SMMT)
Comparing Q2 2026 financial performance, both clinical-stage biotechs maintain robust liquidity, but Arcus currently holds stronger revenue generation and a longer operating runway.
Arcus Biosciences, Inc. reported Q2 2026 revenue of $41 million (down from $160 million in Q2 2025 due to a prior-year catch-up) and a net loss of $91 million. It ended the quarter with $775 million in cash, cash equivalents, and marketable securities, providing cash runway into at least the second half of 2028.
In contrast, Summit Therapeutics Inc. reported no product revenue for Q2 2026 and recorded a GAAP net loss of $215.7 million. Summit closed the quarter with $690.7 million in cash and short-term investments, supported heavily by $230.8 million raised via its ATM equity facility. While both carry zero long-term debt, RCUS is doing better financially due to lower quarterly net losses, established collaboration revenue, and an extended runway without relying as heavily on continuous ATM dilution
Bull Case vs. Bear Case
Arcus Biosciences’ bull case centers on casdatifan, which is demonstrating potential as a backbone HIF-2α inhibitor. Following the company’s second-quarter results, Wedbush raised its price target to $43 from $41 while maintaining an Outperform rating on August 6, citing aggressive program expansion ahead of pivotal clinical readouts expected in October. However, the bear case is that revenue can fluctuate significantly based on partner milestone payments, while the wind-down of domvanalimab’s Phase 3 trials reduces pipeline diversification and increases reliance on other clinical programs.
Summit Therapeutics’ bull case is supported by ivonescimab, which remains one of the more promising PD-1/VEGF bispecific antibodies in development. Momentum strengthened on August 5 when Summit announced an expansion of ivonescimab’s development program into urothelial carcinoma, or bladder cancer, potentially broadening the drug’s commercial opportunity. On the downside, Summit continues to face substantial cash burn, reporting a $215.7 million GAAP net loss in the second quarter. With no commercial revenue, the company may need to continue issuing shares to fund development, creating a risk of significant equity dilution.
Insider Monkey Hedge Fund Data Analysis
Hedge fund sentiment in Q1 2026 favored Arcus Biosciences, Inc. (NYSE:RCUS) over Summit Therapeutics Inc. (NASDAQ:SMMT) in total fund count, though Summit saw expanding interest. Arcus was held by 38 hedge funds in Q1 2026 (up from 37 in Q4 2025). Its top holders include Ken Fisher’s Fisher Asset Management (2,139,396 shares worth ~$65.96 million) and Xin Huang’s Persistent Asset Partners (57,048 shares worth ~$1.76 million).
SMMT saw its hedge fund holder count expand to 34 funds in Q1 2026 (up from 25 in Q4 2025). Major holders include John A. Levin’s Levin Capital Strategies (46,176 shares worth ~$672,784) and Persistent Asset Partners holding call options (2,194 shares equivalent valued at ~$519,509).
Conclusion: What Investors Should Watch Next
Investors should watch Arcus’s upcoming investor event in October for key ARC-20 data readouts for casdatifan combinations. For Summit, investors must track clinical progress following its August ivonescimab expansion announcement alongside cash burn trends heading into late 2026.
While we acknowledge the risk and potential of RCUS as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than RCUS and that has 10,000% upside potential, check out our report about this cheapest AI stock.
READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years
Disclosure: None. Follow Insider Monkey on Google News.
